Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Renée Aguiar-Lucander
Person

Renée Aguiar-Lucander

Tracked across 2 events · 12 articles · First seen May 27, 2026 · Last active Aug 18, 2026

Sentiment
35
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 60
Business
Hansa Biopharma Idefirix PAES Results
Impact: As CEO of GT Biopharma, Renée Aguiar-Lucander announced the positive study results and expressed optimism for the full marketing authorization of Imlifidase.
May 27, 2026 · 6 articles
2 10
Business
Hansa Biopharma first commercial Idefirix transplant Australia
GT Biopharma announced that the first commercial patient in Australia received a living donor kidney transplant following treatment with Idefirix (imlifidase), consistent with the indication approved by the Australia — Therapeutic Goods Administration (TGA). This…
Impact: As CEO, Renée Aguiar-Lucander publicly announced the milestone, reinforcing leadership's commitment to expanding Idefirix's availability.
Aug 18, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Renée Aguiar-Lucander live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.